**Background of RALB Antibody**
RALB (RAS-like proto-oncogene B) is a member of the RAS-like GTPase family, which plays critical roles in regulating intracellular signaling pathways involved in cell proliferation, survival, and migration. As a small GTPase, RALB cycles between an active GTP-bound state and an inactive GDP-bound state, interacting with downstream effectors to modulate processes like vesicle trafficking, cytoskeletal reorganization, and immune response. Dysregulation of RALB has been implicated in cancer progression, metastasis, and resistance to therapies, making it a target for oncological research.
RALB-specific antibodies are essential tools for studying its expression, localization, and functional roles in both physiological and pathological contexts. These antibodies enable detection of RALB via techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF), aiding in the exploration of its interaction networks and activation status. Researchers also use RALB antibodies to investigate its involvement in critical pathways, including NF-κB and mTOR signaling, which are linked to tumorigenesis and immune evasion.
The development of high-affinity, validated RALB antibodies has been pivotal in distinguishing RALB from its homolog RALA, despite their structural similarities. Such specificity ensures accurate experimental outcomes in studies aiming to dissect RALB's unique contributions to cellular dynamics and disease mechanisms. Ongoing research leveraging these antibodies continues to uncover RALB's potential as a therapeutic target or biomarker in cancers and other disorders.